Sadly we don't have an equivalent for privately traded firms.
In general, I think all derivatives should be taxed the equivalent of casino tax, because that's what it is: betting in a zero-sum game for society. Of couse we know that betting provides very good predictive information, but that does not seem like a good reason to treat financial betting different from other form of gambling.
One could make a strong argument that shorting prevents some shareholders from taking a much bigger loss. Some shareholders would have purchased in this hypothetical run-up that short sales would soften. When "it turns out this company is worth much less that they hoped and payed for," those shareholders would lose more because the difference between what they paid and what it's worth would be larger.
That's particularly true for the quintessential long-term retail investor who fundamentally believes in the company. That person is likely going to own it until the company's product is proven or disproven, and the fluctuations in between aren't going to affect them (other than as above, if they bought at an inflated price).
Shorting also creates an incentive for skepticism. One could argue that, if Theranos' technology doesn't work, making it harder and more expensive (dilutive) for them to raise money is a service to society.
[1]: an arguable exception is shorting solely to make other investors lose confidence (rather than due to a negative view of the company). However (a) that's not the case here, (b) often it's actually the undiscovered seed of a real issue (someone has to be first..), and (c) shorting enough of a stock to meaningfully depress it is much, much tougher to do than it sounds, since the short investor will need to purchase/repay shares at some point, the possible exposure when they do is unbounded, and they'll need capital to cover their unrealized loss in the interim. This is not a trade anyone takes lightly.
Anyway, in these situations the response from the company often gives the best indication of how genuinely dire things are. In my experience, Theranos' response has been really, really worrisome. The hasty Cramer appearance (Mad Money??? Uhhh, this isn't a public company). The lawyered-up non-denials and general evasiveness. The editing of the website. The world's most expensive attorneys. The threats to the now-deceased co-founder (realize this was not a response to the WSJ, but still). The reluctant bending to FDA requests.
If this company was public it would be my largest short.